Asia-Pacific Radiotherapy Market, By Type (External-Beam Radiation Therapy, Internal Radiation Therapy, Systemic Radiotherapy/ Radiopharmaceuticals, Others), Product (External Beam Radiotherapy, Internal Radiotherapy Products, Radiotherapy Software, Systemic Radiotherapy Others), Application (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma, Liver Cancer, Thyroid Cancer, Brain Cancer, Cervical Cancer, Spine Cancer, Others), End User (Hospitals, Radiation Therapy Centers, Specialty Clinics, Others), Distribution Channel (Direct Tender, Retail Sales, Others), Country (China, Japan, India, Australia, South Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam and Rest of Asia-Pacific), Industry Trends and Forecast to 2029
Market Analysis and Insights: Asia-Pacific Radiotherapy Market
Asia-Pacific radiotherapy market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.8% in the forecast period of 2022 to 2029 and is expected to reach USD 2,577.50 million by 2029 from USD 1,543.10 million in 2021. Novel technology in radiotherapy for cancer treatment, rising preference for non-surgical procedures are the major drivers which are expected to propel the demand of the market in the forecast period.
Radiotherapy treatment is mainly used for the treatment of cancer disease with the usage of X-rays along with similar forms of radiation technology. In radiotherapy treatment, high-energy based radiation rays are used to damage cells causing cancer and stop them from growing and dividing. Radiotherapy treatment has numerous types of benefits to aim accurately and directly locate cancer wherever it might be in the body. The radiotherapy procedure have seen advancements in terms of launching new treatment planning software and advanced features-based therapy modalities, which require highly skilled and certified professionals to easily operate these products and software.
Radiotherapy demand has increased as compared to the precise year with the increasing demand of radiotherapy in along with the increasing prevalence of cancer disease around the world. In addition, the demand for radiotherapy has increased with rising preference for non-surgical procedures for cancer treatment For Instance: According to the National Center for Biotechnology Information, radiotherapy cancer treatment has the potential to improve the cure rates by 3.5 million cancer patients, and it also improves palliative relief for an additional 3.5 million cancer patients, which is increasing by more than 14 million new cancer cases each year. However, the high cost of the radiotherapy device and panels may hinder the usage of radiotherapy and is expected to slow down the growth of the radiotherapy market in the forecast period.
Increasing cases of cancers globally and wide applications of radiotherapies are expected to provide an opportunity for the market. On the other hand, stringent government regulations for radioactive products are expected to act as a challenge for medical devices in the radiotherapy market.
The Asia-Pacific radiotherapy market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Radiotherapy Market Scope and Market Size
Asia-Pacific Radiotherapy market is segmented into five notable segments, which are based on type, product, application, end user, and distribution channel.
- On the basis of type, the Asia-Pacific radiotherapy market is segmented into external-beam radiation therapy, internal radiation therapy, systemic radiotherapy/radiopharmaceuticals, and others. In 2022, external-beam radiation therapy segment is expected to dominate in the market due to the high adoption of external-beam radiation therapy for the treatment of breast cancer, lung cancer, prostate cancer, colorectal cancer, lymphoma, liver cancer, thyroid cancer, brain cancer, cervical cancer, and spine cancer among others. Further, external-beam radiation therapy is majorly performed during outpatient visits to the treatment center or hospital.
- On the basis of product, the Asia-Pacific radiotherapy market is segmented into external beam radiotherapy, internal radiotherapy products, radiotherapy software, systemic radiotherapy, and others. In 2022, the external beam radiotherapy segment is expected to dominate the market due to the increasing demand for external-beam radiation therapy devices such as linac, proton therapy, cyberknife, gamma knife for the treatment of breast cancer, lung cancer, prostate cancer, colorectal cancer, lymphoma, liver cancer, thyroid cancer, brain cancer, cervical cancer, and spine cancer among others. Further, a rise in the number of cancer patients across the world is anticipated to external beam radiotherapy demand for therapeutics.
- On the basis of application, the Asia-Pacific radiotherapy market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, lymphoma, liver cancer, thyroid cancer, brain cancer, cervical cancer, spine cancer, and others. In 2022, the breast cancer segment is expected to dominate the market due to the increasing prevalence of breast cancer across the world, as breast cancer is the most common cancer in women worldwide.
- On the basis of end user, the Asia-Pacific radiotherapy market is segmented into hospitals, radiation therapy centers, specialty clinics, and others. In 2022, the hospitals' segment is expected to dominate the market as the radiotherapy procedure is performed as an outpatient procedure in the hospital that normally takes less than 60 minutes. Also, hospitals are one of the first contact points and the most trustable option for patients in various countries for the treatment of cancer disease.
- On the basis of distribution channel, the Asia-Pacific radiotherapy market is segmented into direct tender, retail sales, and others. In 2022, the direct tender segment is expected to dominate the market as most of the hospitals, radiation therapy centers, specialty clinics, ambulatory surgical centers, and academic and research organizations prefer direct tender for seeking the benefits of bulk buying, discounts, and easily availability of products.
Asia-Pacific Radiotherapy Market Country Level Analysis
The Asia-Pacific radiotherapy market is analyzed, and market size information is provided by type, product, application, end user, and distribution channel.
The countries covered in the Radiotherapy market report are Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, and rest of Asia-Pacific.
Asia-Pacific is expected to grow with the highest CAGR in the forecast period as in the Asia-Pacific region, the demand for radiotherapy is increasing very rapidly. China is expected to dominate the Asia-Pacific radiotherapy market as China is one of the leading countries in the world with a rapidly increasing diagnosis rate with rising government initiatives for awareness regarding the importance of diagnosis.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Strategic Collaboration and Product Launch By Manufactures Is Creating New Opportunities For Players In The Radiotherapy Market
Asia-Pacific radiotherapy market also provides you with detailed market analysis for every country's growth in the aesthetic industry with Radiotherapy sales, the impact of advancement in radiotherapy, and changes in regulatory scenarios with their support for the Asia-Pacific radiotherapy market. The data is available for the historic period 2011 to 2020.
Competitive Landscape and Asia-Pacific Radiotherapy Market Share Analysis
Asia-Pacific radiotherapy market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the Asia-Pacific radiotherapy market.
The major players covered in the report are CANON MEDICAL SYSTEMS CORPORATION, P-Cure, Mevion Medical Systems, VIEWRAY TECHNOLOGIES, INC. (“VIEWRAY”), Elekta AB (pub), Accuray Incorporated, IBA Worldwide, Eckert & Zeigler BEBIG, Xoft, a subsidiary of iCAD, Inc., RaySearch Laboratories, Brainlab, Advanced Oncotherapy, Hitachi, LTD., Advanced Accelerator Applications (A Subsidiary of Novartis AG), Sumitomo Heavy Industries, Ltd., Siemens Healthcare GmbH, Koninklijke Philips N.V., Panacea Medical Technologies Pvt. Ltd., ZEISS International, General Electric Company, SIT-S.I.T. Sordina IORT Technologies S.p.A., CIVCO Radiotherapy, among other domestic and Asia-Pacific players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launches and agreements are also initiated by the companies worldwide, which are also accelerating the Asia-Pacific radiotherapy market.
For instance,
- In September 2019, Siemens Healthcare GmbH introduced two dedicated CT systems, Somatom go.Sim and Somatom go.Open Pro for the radiation therapy planning. The new system makes radiotherapy planning more accurate. By launching new products, the company has enhanced its product portfolio and generated adequate revenue into the market
- In June 2020, Accuray Incorporated launched CyberKnife S7 System, which is an advanced innovative device for real-time artificial intelligence (AI)-driven motion tracking and synchronization treatment delivery for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments. With launching a new product, the company enhanced its product portfolio and generated adequate revenue
Collaboration, joint ventures, and other strategies by the market player are enhancing the company market in the Radiotherapy market, which also provides the benefit for the organization to improve their offering for radiotherapy.
Customization Available: Asia-Pacific Radiotherapy Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
SKU-